URGN
UroGen Pharma Ltd.
NasdaqGMUSDEQUITY
DELAYED
Last price
46.86
▲ 0.06 (0.13%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
46.55
Prev close
46.80
Day high
47.28
Day low
45.60
Volume
734.06K
Market cap
—
P/E (TTM)
—
52W range
15.86 – 50.81
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
-2.82%
-1.5%
1M
+10.26%
+6.5%
3M
+56.83%
+53.7%
6M
+122.40%
+111.3%
YTD
+100.09%
+87.8%
1Y
+142.67%
+122.7%
3Y
+118.26%
+44.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $109.79M | $90.40M | $82.71M | $64.36M | +21.4% |
| Operating revenue | $109.79M | $90.40M | $82.71M | $64.36M | +21.4% |
| Cost of revenue | $12.45M | $8.88M | $9.36M | $7.65M | +40.2% |
| Gross profit | $97.34M | $81.52M | $73.35M | $56.70M | +19.4% |
| Research & development | $67.11M | $57.15M | $45.61M | $52.91M | +17.4% |
| Selling, general & admin | $155.10M | $121.15M | $93.27M | $82.84M | +28.0% |
| Total operating expense | $222.20M | $178.30M | $138.89M | $135.74M | +24.6% |
| Operating income | -$124.86M | -$96.78M | -$65.54M | -$79.04M | -29.0% |
| Net interest income | -$27.88M | -$27.03M | -$33.63M | -$29.06M | -3.2% |
| Pre-tax income | -$153.42M | -$124.04M | -$98.32M | -$108.03M | -23.7% |
| Tax provision | $78.00K | $2.83M | $3.92M | $1.75M | -97.2% |
| Net income | -$153.49M | -$126.87M | -$102.24M | -$109.78M | -21.0% |
| Net income to common | -$153.49M | -$126.87M | -$102.24M | -$109.78M | -21.0% |
| Basic EPS | -3.19 | -2.96 | -3.55 | -4.79 | -7.8% |
| Diluted EPS | -3.19 | -2.96 | -3.55 | -4.79 | -7.8% |
| EBIT | -$138.07M | -$111.52M | -$83.61M | -$99.59M | -23.8% |
| EBITDA | -$135.66M | -$110.33M | -$81.90M | -$97.77M | -23.0% |
| Basic shares | 48.12M | 42.88M | 28.83M | 22.81M | +12.2% |
| Diluted shares | 48.12M | 42.88M | 28.83M | 22.81M | +12.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $110.75M | $171.99M | $95.00M | $55.41M | -35.6% |
| Cash & short-term investments | $120.46M | $236.69M | $136.97M | $99.96M | -49.1% |
| Accounts receivable | $33.08M | $20.30M | $15.44M | $12.70M | +62.9% |
| Inventory | $16.46M | $9.23M | $5.67M | $4.33M | +78.4% |
| Total current assets | $186.02M | $276.13M | $169.19M | $128.91M | -32.6% |
| Property, plant & equipment | $9.09M | $3.79M | $2.36M | $3.75M | +140.0% |
| Total assets | $200.46M | $285.71M | $178.31M | $135.62M | -29.8% |
| Total current liabilities | $46.42M | $45.95M | $31.21M | $23.92M | +1.0% |
| Long-term debt | $122.21M | $121.73M | $98.55M | $97.54M | +0.4% |
| Total debt | $128.33M | $123.39M | $99.39M | $99.12M | +4.0% |
| Total liabilities | $305.93M | $294.51M | $243.52M | $224.98M | +3.9% |
| Retained earnings | -$959.72M | -$806.22M | -$679.35M | -$577.10M | -19.0% |
| Shareholder equity | -$105.47M | -$8.80M | -$65.21M | -$89.36M | -1,098.2% |
| Working capital | $139.61M | $230.19M | $137.97M | $104.99M | -39.4% |
| Net tangible assets | -$105.47M | -$8.80M | -$65.21M | -$89.36M | -1,098.2% |
| Shares issued | 48.35M | 42.23M | 32.49M | 23.13M | +14.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$153.49M | -$126.87M | -$102.24M | -$109.78M | -21.0% |
| Depreciation & amortisation | $2.41M | $1.19M | $1.71M | $1.82M | +103.3% |
| Stock-based compensation | $11.96M | $13.11M | $9.34M | $10.58M | -8.8% |
| Change in working capital | -$27.91M | $4.93M | $3.34M | -$6.31M | -665.9% |
| Operating cash flow | -$162.44M | -$96.77M | -$76.38M | -$87.56M | -67.9% |
| Capital expenditure | -$289.00K | -$295.00K | -$194.00K | -$254.00K | +2.0% |
| Investing cash flow | $61.56M | -$20.61M | -$953.00K | $1.06M | +398.6% |
| Financing cash flow | $39.92M | $194.62M | $116.93M | $97.13M | -79.5% |
| Free cash flow | -$162.73M | -$97.06M | -$76.57M | -$87.81M | -67.7% |
| End cash position | $112.09M | $173.06M | $95.82M | $56.22M | -35.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $72.46M | $50.96M | $37.84M | $27.48M | $24.21M | +42.2% |
| Operating revenue | $72.46M | $50.96M | $37.84M | $27.48M | $24.21M | +42.2% |
| Cost of revenue | $6.57M | $4.14M | $3.29M | $3.28M | $3.55M | +58.8% |
| Gross profit | $65.88M | $46.82M | $34.55M | $24.20M | $20.66M | +40.7% |
| Research & development | $17.34M | $15.60M | $14.31M | $14.01M | $18.91M | +11.1% |
| Selling, general & admin | $48.44M | $51.49M | $39.35M | $37.58M | $43.20M | -5.9% |
| Total operating expense | $65.77M | $67.08M | $53.66M | $51.59M | $62.11M | -2.0% |
| Operating income | $111.00K | -$20.26M | -$19.11M | -$27.39M | -$41.45M | +100.5% |
| Net interest income | -$8.49M | -$7.76M | -$7.52M | -$6.82M | -$7.10M | -9.4% |
| Pre-tax income | -$8.72M | -$28.35M | -$26.64M | -$34.40M | -$48.92M | +69.2% |
| Tax provision | $5.63M | -$4.77M | -$275.00K | -$1.05M | $1.01M | +218.0% |
| Net income | -$14.35M | -$23.57M | -$26.36M | -$33.35M | -$49.94M | +39.1% |
| Net income to common | -$14.35M | -$23.57M | -$26.36M | -$33.35M | -$49.94M | +39.1% |
| Basic EPS | -0.28 | -0.47 | -0.54 | -0.69 | -1.05 | +40.4% |
| Diluted EPS | -0.28 | -0.47 | -0.54 | -0.69 | -1.05 | +40.4% |
| EBIT | -$3.83M | -$24.16M | -$22.87M | -$31.03M | -$44.79M | +84.1% |
| EBITDA | -$3.17M | -$23.51M | -$22.19M | -$30.39M | -$44.20M | +86.5% |
| Basic shares | 50.38M | 50.18M | 49.23M | 48.06M | 47.74M | +0.4% |
| Diluted shares | 50.38M | 50.18M | 49.23M | 48.06M | 47.74M | +0.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $79.13M | $109.97M | $110.75M | $90.04M | $92.90M | -28.0% |
| Cash & short-term investments | $107.97M | $140.27M | $120.46M | $127.03M | $156.95M | -23.0% |
| Accounts receivable | $88.76M | $55.41M | $33.08M | $19.70M | $19.65M | +60.2% |
| Inventory | $24.59M | $20.92M | $16.46M | $8.34M | $7.13M | +17.5% |
| Total current assets | $235.43M | $237.46M | $186.02M | $168.55M | $196.87M | -0.9% |
| Property, plant & equipment | $8.22M | $8.56M | $9.09M | $9.18M | $6.24M | -3.9% |
| Total assets | $252.59M | $253.69M | $200.46M | $185.05M | $208.72M | -0.4% |
| Total current liabilities | $61.91M | $50.63M | $46.42M | $42.24M | $47.55M | +22.3% |
| Long-term debt | $188.73M | $189.53M | $122.21M | $122.11M | $122.51M | -0.4% |
| Total debt | $196.13M | $195.18M | $128.33M | $128.35M | $125.92M | +0.5% |
| Total liabilities | $384.99M | $377.94M | $305.93M | $300.45M | $302.09M | +1.9% |
| Retained earnings | -$997.64M | -$983.29M | -$959.72M | -$933.35M | -$900.00M | -1.5% |
| Shareholder equity | -$132.40M | -$124.25M | -$105.47M | -$115.41M | -$93.38M | -6.6% |
| Working capital | $173.51M | $186.83M | $139.61M | $126.30M | $149.32M | -7.1% |
| Net tangible assets | -$132.40M | -$124.25M | -$105.47M | -$115.41M | -$93.38M | -6.6% |
| Shares issued | 48.72M | 48.71M | 48.35M | 46.78M | 46.20M | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$14.35M | -$23.57M | -$26.36M | -$33.35M | -$49.94M | +39.1% |
| Depreciation & amortisation | $668.00K | $652.00K | $679.00K | $639.00K | $596.00K | +2.5% |
| Stock-based compensation | $5.33M | $4.63M | $3.13M | $3.03M | $2.73M | +15.2% |
| Change in working capital | -$24.57M | -$30.08M | -$17.06M | -$13.50M | $5.24M | +18.3% |
| Operating cash flow | -$33.01M | -$45.32M | -$38.33M | -$42.27M | -$39.83M | +27.2% |
| Capital expenditure | -$60.00K | -$54.00K | -$17.00K | -$87.00K | -$141.00K | -11.1% |
| Investing cash flow | $1.67M | -$20.69M | $27.72M | $31.40M | $28.41M | +108.1% |
| Financing cash flow | $500.00K | $65.20M | $31.32M | $8.27M | $296.00K | -99.2% |
| Free cash flow | -$33.07M | -$45.37M | -$38.34M | -$42.36M | -$39.97M | +27.1% |
| End cash position | $80.46M | $111.30M | $112.09M | $91.39M | $93.99M | -27.7% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
48.08
-2.53% from price
SMA 20
45.02
+4.09% from price
SMA 50
40.27
+16.38% from price
SMA 100
32.76
+43.06% from price
SMA 200
27.18
+72.41% from price
EMA 12
47.04
-0.39% from price
EMA 26
44.53
+5.24% from price
EMA 50
40.69
+15.16% from price
RSI (14)
58.1
Neutral
MACD (12,26,9)
2.52
Hist -0.13
ATR (14)
2.52
5.37% of price
Realised vol 30D
62.8%
Annualised
Bollinger upper
52.68
20, 2σ
Bollinger lower
37.35
20, 2σ
50 / 200 cross
Golden
40.27 vs 27.18
Trend bias
Above 200
+72.41%
Risk profile
Beta vs SPY
1.15
More volatile than market
Correlation to SPY
0.22
Largely independent
Realised vol 30D
62.8%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-42.2%
Peak to trough
Max drawdown 5Y
-82.6%
Peak to trough
ATR 14
2.52
5.37% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet
Zacks · 1d ago
UroGen Signs Investment, Collaboration Agreements With IntraGel for Access to Sustained-Release Platform
MT Newswires · 3d ago
IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies
PR Newswire · 3d ago
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline
GlobeNewswire · 3d ago
Sector Update: Healthcare Stocks Mixed Monday Afternoon
MT Newswires · 5d ago
Sector Update: Healthcare
MT Newswires · 5d ago
UroGen Pharma Submits US FDA New Drug Application for UGN-103 in Recurrent Bladder Cancer
MT Newswires · 5d ago
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC
GlobeNewswire · 6d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.